These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 32271671)
1. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. Wagner LI; Gray RJ; Sparano JA; Whelan TJ; Garcia SF; Yanez B; Tevaarwerk AJ; Carlos RC; Albain KS; Olson JA; Goetz MP; Pritchard KI; Hayes DF; Geyer CE; Dees EC; McCaskill-Stevens WJ; Minasian LM; Sledge GW; Cella D J Clin Oncol; 2020 Jun; 38(17):1875-1886. PubMed ID: 32271671 [TBL] [Abstract][Full Text] [Related]
2. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Garcia SF; Gray RJ; Sparano JA; Tevaarwerk AJ; Carlos RC; Yanez B; Gareen IF; Whelan TJ; Sledge GW; Cella D; Wagner LI Cancer; 2022 Feb; 128(3):536-546. PubMed ID: 34614209 [TBL] [Abstract][Full Text] [Related]
8. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Le Rhun E; Delbeuck X; Lefeuvre-Plesse C; Kramar A; Skrobala E; Pasquier F; Bonneterre J Breast Cancer Res Treat; 2015 Aug; 152(3):569-80. PubMed ID: 26160250 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. Francis PA Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169 [TBL] [Abstract][Full Text] [Related]
10. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status. Nomura Y; Shirouzu M; Takayama T Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611 [TBL] [Abstract][Full Text] [Related]
11. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148 [TBL] [Abstract][Full Text] [Related]
12. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS; Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680 [TBL] [Abstract][Full Text] [Related]
13. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. Hayes DF Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G; Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056 [TBL] [Abstract][Full Text] [Related]
16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant endocrine therapy for postmenopausal women: Type and duration. Mayer EL; Burstein HJ Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133 [TBL] [Abstract][Full Text] [Related]
18. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. Colleoni M; Munzone E Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891 [TBL] [Abstract][Full Text] [Related]
19. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. International Breast Cancer Study Group (IBCSG) J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096 [TBL] [Abstract][Full Text] [Related]
20. 21. The adjuvant treatment of breast cancer. Kelleher M; Miles D Int J Clin Pract; 2003 Apr; 57(3):195-9. PubMed ID: 12723723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]